Literature DB >> 16715139

Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.

N Mise1, M Drosten, T Racek, A Tannapfel, B M Pützer.   

Abstract

Distinct dominant activating mutations in the RET proto-oncogene are responsible for the development of multiple endocrine neoplasia type 2 (MEN 2). Concise examination of the mutated codons led to the detection of a striking genotype-phenotype correlation between the mutated codon and the MEN 2 phenotype in terms of onset and aggressiveness of the disease, suggesting that manifestation and clinical progression is conditioned by the type of mutation. To gain insight into the molecular basis for this genotype-phenotype correlation, we analysed the impact of common and rare mutations identified in MEN 2A (C609Y, C634R), MEN 2B (A883F, M918T) and familial medullary thyroid carcinoma (Y791F) patients on several aspects of cell transformation, including proliferation, apoptosis, anchorage-independent growth and signaling. We found that tumor cells arising from distinct extracellular or intracellular MEN 2 mutations clearly differ in their proliferation properties owing to the activation of different molecular pathways, but importantly, also in resistance to apoptosis. Whereas MEN 2A mutants resulted in accelerated cell proliferation, MEN 2B-RET mutants significantly enhanced suppression of apoptosis, which may account, at least partially, for some of the clinical differences in MEN 2 patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715139     DOI: 10.1038/sj.onc.1209669

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Review.

Authors:  Sujal Rangwalla; Cheryl E Gariepy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

2.  Rap1GAP interacts with RET and suppresses GDNF-induced neurite outgrowth.

Authors:  Li Jiao; Yong Zhang; Chun Hu; Yong-Gang Wang; Aijun Huang; Cheng He
Journal:  Cell Res       Date:  2010-09-28       Impact factor: 25.617

3.  Hirschsprung's disease and medullary thyroid carcinoma: 15-year experience with molecular genetic screening of the RET proto-oncogene.

Authors:  Eliska Vaclavikova; Lucie Kavalcova; Richard Skaba; Sarka Dvorakova; Pavla Macokova; Blanka Rouskova; Bela Bendlova
Journal:  Pediatr Surg Int       Date:  2012-02       Impact factor: 1.827

Review 4.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

5.  The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.

Authors:  William Grey; Rosaline Hulse; Anna Yakovleva; Dilyana Genkova; Benjamin Whitelaw; Ellen Solomon; Salvador J Diaz-Cano; Louise Izatt
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 6.  Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.

Authors:  Ying-Hsia Chu; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

7.  High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

Authors:  Lei Ye; Libero Santarpia; Gilbert J Cote; Adel K El-Naggar; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2008-09-02       Impact factor: 5.958

Review 8.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

9.  RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest.

Authors:  Eliska Vaclavikova; Sarka Dvorakova; Vlasta Sykorova; Radovan Bilek; Katerina Dvorakova; Petr Vlcek; Richard Skaba; Tomas Zelinka; Bela Bendlova
Journal:  Endocrine       Date:  2009-10-14       Impact factor: 3.633

Review 10.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.